Investment Rating - The report maintains an investment rating of "Outperform the Market - A" for the life sciences upstream sector [6]. Core Insights - The life sciences upstream sector is experiencing simultaneous domestic substitution and accelerated international expansion, with significant room for improvement in the localization rates of research reagents, consumables, and high-end scientific instruments [1][22]. - The demand side is improving due to favorable trends in innovative drug development and supportive national policies, with domestic innovative drug companies' overseas business development (BD) transactions expected to exceed $100 billion in 2025, nearly doubling from 2024 [2][25]. - The supply side is also gradually improving, with domestic life sciences companies achieving technological breakthroughs and expanding their business pipelines through both organic growth and acquisitions [2][29]. - Key companies are showing signs of performance improvement, with notable growth in revenue and net profit for firms like Baipusais and Aopumai [2][34]. Summary by Sections 1. Life Sciences Upstream Overview - The life sciences upstream includes research reagents, experimental consumables, instruments, and comprehensive services, playing a crucial role in various applications such as antibody drugs and gene therapy [9][10]. 1.1 Domestic Substitution and International Expansion - The localization rates for research reagents are around 10%, with high-end scientific instruments having an import rate of approximately 70.6% [22][23]. 1.2 Demand Side Improvement - The innovative drug sector is witnessing a recovery, with significant increases in overseas BD transactions, indicating a robust demand for life sciences products [25][27]. 1.3 Supply Side Enhancements - Domestic companies are making technological advancements, with key players like Aopumai and Baipusais expanding their product lines and market presence through acquisitions and internal development [29][30]. 1.4 Company Performance Trends - Companies such as Baipusais and Aopumai have reported substantial improvements in their financial performance, with Baipusais showing a 31% year-on-year revenue growth and Aopumai achieving a remarkable 402% increase in net profit [34]. 2. Recommended Stocks - Suggested stocks to watch include Baipusais, Aopumai, Aladdin, and others in the research reagent and scientific instrument sectors [2].

Core Insights - Multiple leading companies in the A-share market reported significant net profit growth in the third quarter [1] - The China Securities Regulatory Commission (CSRC) is enhancing regulatory measures to combat cross-border illegal activities in the capital market [1] - The first batch of new registered companies in the Sci-Tech Innovation Board was listed, indicating ongoing reforms in the capital market [2] Company Performance - **世荣兆业**: Q3 revenue reached 593 million yuan, up 235.68%, with net profit of 109 million yuan, up 3168.80% [6] - **纳微科技**: Q3 revenue was 257 million yuan, a 22.46% increase, with net profit of 44.46 million yuan, up 1558.82% [6] - **中国电影**: Q3 revenue was 1.212 billion yuan, up 35.61%, with net profit of 177 million yuan, up 1463.17% [6] - **华钰矿业**: Q3 revenue reached 656 million yuan, up 96.97%, with net profit of 619 million yuan, up 1315.3% [7] - **光线传媒**: Q3 revenue was 374 million yuan, up 247.54%, with net profit of 106 million yuan, up 993.71% [7] - **生益电子**: Q3 revenue reached 3.06 billion yuan, up 153.71%, with net profit of 584 million yuan, up 545.95% [8] - **赣锋锂业**: Q3 revenue was 6.249 billion yuan, up 44.10%, with net profit of 557 million yuan, up 364.02% [9] - **吉比特**: Q3 revenue reached 1.968 billion yuan, up 129.19%, with net profit of 569 million yuan, up 307.7% [10] Market Developments - The total market capitalization of listed companies in the domestic stock market reached 105.99 trillion yuan, the highest in nearly four years [3] - The CSRC is focusing on enhancing the inclusiveness and competitiveness of the capital market to better serve national development goals [2] - The upcoming China International Import Expo will showcase 461 new products and technologies, highlighting future industries [2]

Core Points - Nanwei Technology announced the resignation of Professor Lin Dongqiang from the board of directors due to personal reasons [1] - Following his resignation, Professor Lin will no longer hold any position within the company [1] Summary by Category Company Announcement - The company received a resignation report from Professor Lin Dongqiang, who served on the third board of directors [1] - Professor Lin also resigned from his position on the nomination committee of the third board of directors [1]

Core Insights - Nanwei Technology reported a revenue of 671 million yuan for the first three quarters of 2025, representing a year-on-year growth of 22.01% [1] - The net profit attributable to shareholders reached 108 million yuan, showing a significant increase of 156.56% year-on-year [1] - The company’s basic earnings per share stood at 0.27 yuan [1] Financial Performance - The gross profit margin for the first three quarters of 2025 was 72.16%, up by 1.10 percentage points year-on-year, while the net profit margin was 16.75%, an increase of 9.24 percentage points compared to the same period last year [2] - In Q3 2025, the gross profit margin was 72.32%, reflecting a year-on-year increase of 3.45 percentage points and a quarter-on-quarter increase of 0.85 percentage points [2] - The net profit margin for Q3 2025 was 18.18%, up 19.32% year-on-year and 1.61 percentage points quarter-on-quarter [2] Expense Analysis - Total operating expenses for Q3 2025 amounted to 358 million yuan, an increase of 38.49 million yuan year-on-year [2] - The expense ratio was 53.41%, a decrease of 4.75 percentage points compared to the same period last year [2] - Sales expenses increased by 2.83%, management expenses rose by 26.39%, and R&D expenses grew by 14.20%, while financial expenses decreased by 102.90% [2] Shareholder Information - As of the end of Q3 2025, the total number of shareholders was 16,100, an increase of 992 from the end of the previous half-year, representing a growth of 6.57% [2] - The average market value per shareholder increased from 610,500 yuan at the end of the previous half-year to 724,600 yuan, a rise of 18.70% [2] Company Overview - Nanwei Technology, established on October 22, 2007, is located in Suzhou Industrial Park, Jiangsu Province, and was listed on June 23, 2021 [3] - The company specializes in the research, large-scale production, sales, and application services of high-performance nano-microsphere materials, serving clients in biomedicine, flat panel displays, analytical testing, and in vitro diagnostics [3] - The main business revenue composition includes chromatography fillers and media products (57.62%), chromatography analysis instruments and accessories (19.72%), and other related products and services [3]

Group 1 - The core viewpoint of the article is that 纳微科技 (NANWEI Technology) has reported significant growth in its third-quarter financial results, indicating strong performance in the market [1] Group 2 - For the first three quarters, the company's operating revenue reached 670,760,222.37 yuan, representing a year-on-year increase of 22.01% [1] - The net profit attributable to shareholders of the listed company was 107,767,557.09 yuan, showing a substantial year-on-year increase of 156.56% [1]

证券代码：688690 证券简称：纳微科技 公告编号：2025-037 苏州纳微科技股份有限公司 关于召开2025年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会 议 问 题 征 集 ： 投 资 者 可 于 2025 年 11 月 7 日 前 访 问 网 址 https://eseb.cn/1sJvpnVdc3e 或使用微信扫描下方小程序码进行会前提问，公司 将通过本次业绩说明会，在信息披露允许范围内就投资者普遍关注的问题进行回 答。 一、 说明会类型 苏州纳微科技股份有限公司（以下简称"公司"）已于 2025 年 10 月 29 日发布 公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司经营业绩、 发展战略等情况，公司定于 2025 年 11 月 7 日（星期五）15:00-16:00 在"价值在 线"（www.ir-online.cn）召开苏州纳微科技股份有限公司 2025 年第三季度业绩说 明会，与投资者进行沟通和交流，广泛听取投资者的意见和建议。 二、 ...

证券代码：688690 证券简称：纳微科技 公告编号：2025-034 苏州纳微科技股份有限公司 关于取消监事会、修订《公司章程》并办理工商变更 登记及修订、制定部分公司治理制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 苏州纳微科技股份有限公司（以下简称"公司"）于2025年10月27日召开第 三届董事会第九次会议，审议通过了《关于取消监事会、修订<公司章程>并办理 工商变更登记的议案》《关于修订和制定部分公司治理制度的议案》，现将相关 情况公告如下： 一、取消监事会情况 根据2024年7月1日起实施的《中华人民共和国公司法》（以下简称"《公司 法》"）、中国证监会于2024年12月27日发布的《关于新<公司法>新配套制度规 则实施相关过渡期安排》及《上市公司章程指引（2025年修订）》等法律、法规 及规范性文件要求，结合公司实际情况，公司拟取消监事会，监事会的法定职权 由董事会审计委员会承接，公司《监事会议事规则》相应废止，公司各项规章制 度中涉及监事会、监事的规定不再适用。 在公司股东大会审议通过取消监事 ...

| | | | 原定任期 | | 是否继续在上 | 具体职 | 是否存在未 | | --- | --- | --- | --- | --- | --- | --- | --- | | 姓名 | 离任职务 | 离任时间 | 到期日 | 离任原因 | 市公司及其控 | 务（如 | 履行完毕的 | | | | | | | 股子公司任职 | 适用） | 公开承诺 | | 林东强 | 第三届董事会董 事、第三届董事会 | 2025 年 10 | 2027 年 5 | 个人原因 | 否 | 不适用 | 否 | | | | 月 27 日 | 月 14 日 | | | | | | | 提名委员会委员 | | | | | | | (二) 离任对公司的影响 根据《公司法》《公司章程》及相关规定，林东强教授辞任后不会导致公司 董事会成员低于法定最低人数，不会影响董事会依法规范运作，也不会影响公司 正常的经营发展，林东强教授的辞任报告自送达公司董事会之日起生效。截至本 公告披露之日，林东强教授未持有公司股份，不存在应当履行而未履行的承诺事 证券代码：688690 证券简称：纳微科技 公告编号：2025-035 苏州纳微科技股份有限公 ...

证券代码：688690 证券简称：纳微科技 公告编号：2025-036 苏州纳微科技股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第一次临时股东大会 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 11 月 17 日14 点 30 分 召开地点：江苏省苏州市工业园区百川街 2 号研发中心大楼会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 11 月 17 日 至2025 年 11 月 17 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通 过互联网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 股东大会召开日期：2025年11月17日 本次股东 ...

Group 1 - Company Nanwei Technology (SH 688690) reported Q3 performance with revenue of approximately 671 million yuan, a year-on-year increase of 22.01% [1] - The net profit attributable to shareholders was about 108 million yuan, reflecting a significant year-on-year increase of 156.56% [1] - Basic earnings per share reached 0.2689 yuan, marking a year-on-year increase of 157.32% [1] Group 2 - As of the report, Nanwei Technology's market capitalization stands at 11.9 billion yuan [2]